This phase 3 trial tested weekly tirzepatide in 160 adolescents with obesity, or overweight plus a complication. Across 31 centres in six countries, they were randomised 2:1, double-blind, to tirzepatide or placebo plus lifestyle intervention. At week 72, BMI fell 18.5% with tirzepatide and rose 0.5% with placebo, a 19.0-point difference. BMI fell by at least 5% in 79.6% on tirzepatide and 28.5% on placebo. All 10 key secondary outcomes, including body weight, waist circumference and physical functioning, favoured tirzepatide. Adverse events and discontinuations were recorded, but the abstract supplied ends before reporting them.
Why it is interesting: Tirzepatide is approved for obesity management in adults. This placebo-controlled trial reports its 72-week effect on BMI in adolescents.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.